Biolase (BIOL) Tops Q2 EPS by 109c

Biolase (NASDAQ: BIOL) reported Q2 EPS of ($4.24), $1.09 better than the analyst estimate of ($5.33). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $15.36 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Innovaro (INV) Misses Q2 EPS by 9c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c